Literature DB >> 18841327

A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer.

Bryan H Burmeister1, Euan T Walpole, Nancy D'Arcy, Elizabeth A Burmeister, Sharon Cox, Damien B Thomson, Jennifer A Harvey, B Mark Smithers.   

Abstract

BACKGROUND: Chemoradiation therapy using regimens containing cisplatin and 5-fluorouracil are most commonly used for inoperable cancer of the esophagus. Cisplatin is relatively toxic and is not suitable for many patients. Little data exists using platinum analogues together with protracted infusion 5-fluorouracil and radiation therapy in the curative setting.
METHODS: Fourteen patients with localised oesophageal cancer suitable for curative chemoradiation therapy registered on the study. Chemotherapy consisted of 5-fluorouracil 225 mg/m(2) daily throughout radiation therapy, with oxaliplatin 60 mg/m(2) weekly. The radiation dose was 56 to 60 Gy in 28 to 30 fractions.
RESULTS: The median age of the patients was 70.5 years. Therapy was associated with excessive grade 3 and 4 non-hematologic toxicity. There was one treatment related death. The median progression-free survival was 31.5 months and median overall survival 32.6 months. Six patients achieved a prolonged complete endoscopic and radiological response.
CONCLUSIONS: Although weekly oxaliplatin in combination with infusional 5 fluorouracil produces durable remissions in esophageal cancer, the regimen used in this trial was not acceptable for routine use. Future protocols should incorporate lower chemotherapy doses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18841327     DOI: 10.1007/s10637-008-9178-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  14 in total

1.  Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.

Authors:  David P Ryan; Donna Niedzwiecki; Donna Hollis; Brent E Mediema; Scott Wadler; Joel E Tepper; Richard M Goldberg; Robert J Mayer
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

2.  Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study.

Authors:  L R Coia; B D Minsky; B A Berkey; M J John; D Haller; J Landry; T M Pisansky; C G Willett; J P Hoffman; J B Owen; G E Hanks
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.

Authors:  Bryan H Burmeister; Euan T Walpole; Elizabeth A Burmeister; Janine Thomas; Damien B Thomson; Jennifer A Harvey; B Mark Smithers; David C Gotley
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

4.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

5.  Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity.

Authors:  J MacKean; B H Burmeister; D S Lamb; J W Denham
Journal:  Australas Radiol       Date:  1996-11

6.  Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.

Authors:  Joan Maurel; Andrés Cervantes; Carlos Conill; Ramón Salazar; Marta Martin-Richard; Manuel Pera; Hermini Manzano; Isabel Chirivella; Rosa Gallego; Xavier Marfa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-05-01       Impact factor: 7.038

7.  A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.

Authors:  C Aschele; M L Friso; S Pucciarelli; S Lonardi; L Sartor; G Fabris; E D L Urso; P Del Bianco; G Sotti; M Lise; S Monfardini
Journal:  Ann Oncol       Date:  2005-05-13       Impact factor: 32.976

8.  Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma.

Authors:  Brigid M O'Connor; Manpreet Kaur Chadha; Amitkumar Pande; Jeffrey C Lombardo; Chumy E Nwogu; Hector R Nava; Gary Yang; Milind M Javle
Journal:  Cancer J       Date:  2007 Mar-Apr       Impact factor: 3.360

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.

Authors:  B H Burmeister; J W Denham; M O'Brien; G G Jamieson; P G Gill; P Devitt; E Yeoh; C S Hamilton; S P Ackland; D S Lamb
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

View more
  5 in total

1.  Volumetric modulated arc therapy planning for distal oesophageal malignancies.

Authors:  M A Hawkins; J L Bedford; A P Warrington; D M Tait
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

2.  Multidetector-computed tomography attenuation values between the tumor and aortic wall in response to induction therapy for esophageal cancer and its predictive value for aortic invasion.

Authors:  Hironori Tsujimoto; Takashi Ichikura; Satoshi Aiko; Yoshihisa Yaguchi; Isao Kumano; Risa Takahata; Yusuke Matsumoto; Kazumichi Yoshida; Satoshi Ono; Junji Yamamoto; Kazuo Hase
Journal:  Exp Ther Med       Date:  2011-11-22       Impact factor: 2.447

3.  Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint.

Authors:  Kai Zheng; Yan Li; Shaoxiang Wang; Xiao Wang; Chenghui Liao; Xiaopeng Hu; Long Fan; Qiangrong Kang; Yong Zeng; Xuli Wu; Haiqiang Wu; Jian Zhang; Yifei Wang; Zhendan He
Journal:  Autophagy       Date:  2016-06-16       Impact factor: 16.016

4.  Volumetric modulated arc therapy vs. c-IMRT for the treatment of upper thoracic esophageal cancer.

Authors:  Wu-Zhe Zhang; Tian-Tian Zhai; Jia-Yang Lu; Jian-Zhou Chen; Zhi-Jian Chen; De-Rui Li; Chuang-Zhen Chen
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

5.  Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats.

Authors:  Hassan I El-Sayyad; Mohamed F Ismail; F M Shalaby; R F Abou-El-Magd; Rajiv L Gaur; Augusta Fernando; Madhwa H G Raj; Allal Ouhtit
Journal:  Int J Biol Sci       Date:  2009-06-28       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.